Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaPhilip L. McCarthy, Charles Linker, Sergio Giralt et al.|New England Journal of Medicine|2012Cited by 1.1k
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumoursMichael Warso, Tapas K. Das Gupta, Jon Richards et al.|British Journal of Cancer|2013Cited by 182
Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium StudyRishi Lulla, Maryam Fouladi, Stewart Goldman et al.|Neuro-Oncology|2016Cited by 140